Correlation between Acylcarnitine and Peripheral Neuropathy in Type 2 Diabetes Mellitus
Table 4
Acylcarnitines are associated with DPN in univariate and multivariate analyses.
Model
Factor
OR
95% CI
Model 1
Factor 1
0.91
0.77-1.09
0.309
Factor 2
1.21
1.01-1.44
0.038
Factor 3
0.95
0.79-1.13
0.535
Factor 4
0.83
0.70-1.00
0.046
Factor 5
1.03
0.87-1.23
0.708
Factor 6
0.83
0.69-0.99
0.035
Model 2
Factor 1
0.91
0.76-1.09
0.307
Factor 2
1.21
1.02-1.45
0.036
Factor 3
0.94
0.78-1.31
0.501
Factor 4
0.83
0.69-0.99
0.043
Factor 5
1.04
0.86-1.26
0.670
Factor 6
0.82
0.69-0.98
0.032
Model 3
Factor 1
0.96
0.79-1.17
0.689
Factor 2
1.37
1.12-1.67
0.002
Factor 3
0.94
0.77-1.16
0.582
Factor 4
0.87
0.71-1.06
0.173
Factor 5
1.06
0.86-1.30
0.589
Factor 6
0.87
0.71-1.07
0.179
Model 4
Factor 1
0.97
0.80-1.18
0.754
Factor 2
1.38
1.13-1.69
0.002
Factor 3
0.95
0.77-1.16
0.608
Factor 4
0.86
0.71-1.06
0.152
Factor 5
1.06
0.86-1.30
0.612
Factor 6
0.86
0.71-1.06
0.155
Model 1 was a univariate model; Model 2-Model 4 were multivariate models. Among them, Model 2 adjusted the interaction between acylcarnitines. Model 3 further adjusted for the effects of sex, age, height, weight, BMI, SBP, diabetes course, and HbA1c. On this basis, the influence of diabetes drugs was further adjusted to obtain Model 4.
